Pituitary hypophysitis in granulomatosis with polyangiitis (GPA): a case series.
ANCA-associated vasculitis
Granulomatosis with polyangiitis
Hypophysitis
Rituximab
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
31 Jan 2024
31 Jan 2024
Historique:
accepted:
24
12
2023
medline:
1
2
2024
pubmed:
1
2
2024
entrez:
31
1
2024
Statut:
aheadofprint
Résumé
Granulomatosis with polyangiitis (GPA) rarely involves the pituitary gland. Pituitary involvement has been reported in ~ 1% of all cases of GPA. Most commonly, pituitary swelling and inflammation results in symptoms due to pituitary mass effect and arginine vasopressin deficiency. To date, there are no pituitary-specific treatment guidelines for this rare condition. We present three patients with GPA-related hypophysitis highlighting the spectrum of pituitary involvement. All three patients were successfully treated with immunosuppressive regimens that included rituximab (RTX). Following remission induction with high-dose glucocorticoids, patients received 6 monthly RTX for remission maintenance. RTX was well tolerated without significant side effects.
Identifiants
pubmed: 38296897
doi: 10.1007/s11102-023-01378-5
pii: 10.1007/s11102-023-01378-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11. https://doi.org/10.1002/art.37715
doi: 10.1002/art.37715
pubmed: 23045170
Kitching AR, Anders HJ, Basu N et al (2020) ANCA-associated vasculitis. Nat Rev Dis Primers 6(1):71. https://doi.org/10.1038/s41572-020-0204-y
doi: 10.1038/s41572-020-0204-y
pubmed: 32855422
Kapoor E, Cartin-Ceba R, Specks U, Leavitt J, Erickson B, Erickson D (2014) Pituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic experience. J Clin Endocrinol Metab 99(11):3988–3994. https://doi.org/10.1210/jc.2014-1962
doi: 10.1210/jc.2014-1962
pubmed: 25077899
De Parisot A, Puechal X, Langrand C et al (2015) Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. Medicine (Baltimore) 94(16):e748. https://doi.org/10.1097/MD.0000000000000748
doi: 10.1097/MD.0000000000000748
pubmed: 25906106
Vega-Beyhart A, Medina-Rangel IR, Hinojosa-Azaola A et al (2020) Pituitary dysfunction in granulomatosis with polyangiitis. Clin Rheumatol 39(2):595–606. https://doi.org/10.1007/s10067-019-04735-7
doi: 10.1007/s10067-019-04735-7
pubmed: 31446541
Baird SM, Pratap U, McLean C, Law CP, Maartens N (2017) Rare presentation of Wegener’s granulomatosis in the pituitary gland: case report and literature review. Int J Surg Case Rep 33:24–26. https://doi.org/10.1016/j.ijscr.2017.02.014
doi: 10.1016/j.ijscr.2017.02.014
pubmed: 28273603
pmcid: 5338910
Hellmich B, Sanchez-Alamo B, Schirmer JH et al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223764
doi: 10.1136/ard-2022-223764
Specks U, Merkel PA, Seo P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369(5):417–427. https://doi.org/10.1056/NEJMoa1213277
doi: 10.1056/NEJMoa1213277
pubmed: 23902481
pmcid: 5953195
Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232. https://doi.org/10.1056/NEJMoa0909905
doi: 10.1056/NEJMoa0909905
pubmed: 20647199
pmcid: 3137658
Ponte C, Grayson PC, Robson JC et al (2022) American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis Rheumatol 74(12):1881–1889. https://doi.org/10.1002/art.42325
doi: 10.1002/art.42325
pubmed: 36350123
Idolor ON, Guraya A, Muojieje CC et al (2021) Renal involvement in granulomatosis with polyangiitis increases economic health care burden: insights from the national inpatient sample database. Cureus 13(1):e12515. https://doi.org/10.7759/cureus.12515
doi: 10.7759/cureus.12515
pubmed: 33564520
pmcid: 7863020
Peters JE, Gupta V, Saeed IT, Offiah C, Jawad ASM (2018) Severe localised granulomatosis with polyangiitis (Wegener’s granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review. BMC Neurol 18(1):59. https://doi.org/10.1186/s12883-018-1058-8
doi: 10.1186/s12883-018-1058-8
pubmed: 29716529
pmcid: 5930853
Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS (2012) Progression and management of Wegener’s granulomatosis in the head and neck. Laryngoscope 122(8):1695–1700. https://doi.org/10.1002/lary.23273
doi: 10.1002/lary.23273
pubmed: 22674560
Borner U, Landis BN, Banz Y et al (2012) Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener’s granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy 26(6):475–480. https://doi.org/10.2500/ajra.2012.26.3825
doi: 10.2500/ajra.2012.26.3825
pubmed: 23232198
Zheng Y, Zhang Y, Cai M, Lai N, Chen Z, Ding M (2018) Central nervous system involvement in ANCA-associated vasculitis: what neurologists need to know. Front Neurol 9:1166. https://doi.org/10.3389/fneur.2018.01166
doi: 10.3389/fneur.2018.01166
pubmed: 30687221
Hong E, Shalid A, Gatt D, Deepak S, Bahl A (2021) Primary pituitary granulomatosis with polyangiitis and the role of pituitary biopsy, case report and literature review. Br J Neurosurg. https://doi.org/10.1080/02688697.2021.1878345
doi: 10.1080/02688697.2021.1878345
pubmed: 34253094
Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR (1995) The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 123(12):925–32
Pakalniskis MG, Berg AD, Policeni BA et al (2015) The many faces of granulomatosis with polyangiitis: a review of the head and neck imaging manifestations. AJR Am J Roentgenol 205(6):W619–W629. https://doi.org/10.2214/AJR.14.13864
doi: 10.2214/AJR.14.13864
pubmed: 26587951
Chung SA, Gorelik M, Langford CA et al (2021) American college of rheumatology/vasculitis foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol 73(8):1384–1393. https://doi.org/10.1002/art.41776
doi: 10.1002/art.41776
pubmed: 34235883
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM (2021) Kidney disease: improving global outcomes glomerular diseases. Kidney Int 100(4S):S1–S276
doi: 10.1016/j.kint.2021.05.021
Mukhtyar C, Lee R, Brown D et al (2009) Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 68(12):1827–1832. https://doi.org/10.1136/ard.2008.101279
doi: 10.1136/ard.2008.101279
pubmed: 19054820
Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371(19):1771–1780. https://doi.org/10.1056/NEJMoa1404231
doi: 10.1056/NEJMoa1404231
pubmed: 25372085
Yates M, Watts R (2017) ANCA-associated vasculitis. Clin Med (Lond) 17(1):60–64. https://doi.org/10.7861/clinmedicine.17-1-60
doi: 10.7861/clinmedicine.17-1-60
pubmed: 28148583
Charles P, Terrier B, Perrodeau E et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77(8):1143–1149. https://doi.org/10.1136/annrheumdis-2017-212878
doi: 10.1136/annrheumdis-2017-212878
pubmed: 29695500
Jones RB, Furuta S, Tervaert JW et al (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74(6):1178–1182. https://doi.org/10.1136/annrheumdis-2014-206404
doi: 10.1136/annrheumdis-2014-206404
pubmed: 25739829
McAdoo SP, Medjeral-Thomas N, Gopaluni S et al (2018) Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transpl 33(5):899
doi: 10.1093/ndt/gfy075
Gulati K, Edwards H, Prendecki M et al (2021) Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 100(6):1316–1324. https://doi.org/10.1016/j.kint.2021.08.025
doi: 10.1016/j.kint.2021.08.025
pubmed: 34560140
Cortazar FB, Muhsin SA, Pendergraft WF 3rd et al (2018) Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep 3(2):394–402. https://doi.org/10.1016/j.ekir.2017.11.004
doi: 10.1016/j.ekir.2017.11.004
pubmed: 29725643
Gendreitzig P, Honegger J, Quinkler M (2020) Granulomatous hypophysitis causing compression of the internal carotid arteries reversible with azathioprine and rituximab treatment. Pituitary 23(2):103–112. https://doi.org/10.1007/s11102-019-01005-2
doi: 10.1007/s11102-019-01005-2
pubmed: 31748928
Smith RM, Jones RB, Specks U et al (2023) Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis 82(7):937–944. https://doi.org/10.1136/ard-2022-223559
doi: 10.1136/ard-2022-223559
pubmed: 36958796
Jayne DRW, Merkel PA, Schall TJ, Bekker P, Group AS (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599–609. https://doi.org/10.1056/NEJMoa2023386
doi: 10.1056/NEJMoa2023386